Which Patients have Greatest Need for Elvitegravir/Cobicistat/ Emtricitabine/TenofovirDF-Based Therapy?

ISSN: 2212-4071 (Online)
ISSN: 1574-891X (Print)

Volume 12, 2 Issues, 2017

Download PDF Flyer

Recent Patents on Anti-Infective Drug Discovery

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

Dieter Kabelitz
Institute of Immunology
Universitätsklinikum Schleswig-Holstein
Campus Kiel
Arnold-Heller-Straße 3
Kiel, D-24105

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Which Patients have Greatest Need for Elvitegravir/Cobicistat/ Emtricitabine/TenofovirDF-Based Therapy?

Recent Patents on Anti-Infective Drug Discovery, 9(1): 41-51.

Author(s): Antonio Di Biagio, Roberta Prinapori, Lucia Taramasso, Giulia Gustinetti, Laura Sticchi, Bianca Bruzzone and Claudio Viscoli.

Affiliation: InfectiousDiseases Unit, IRCCS A.O.U. San Martino- IST, Genoa, Italy, Largo R. Benzi, 10, 16132 Genoa, Italy.


Elvitegravir/cobicistat/emtricitabine/tenofovirDF (EVG/COBI/FTC/TDF) is the new single-tablet, fixed-dose formulation containing an integrase strand transfer inhibitor recently approved as antiretroviral treatment. In this paper we analysed its use and advantages in naïve and experienced HIV-infected patients and we focused on special populations in which EVG/COBI/FTC/TDF could be a suitable option. Furthermore the manuscript reports the recent patent of EVG which may have an influence on the management of HIV-infected patients in the next future.


Cobicistat, elvitegravir, emtricitabine, resistance, side effects, tenofovirDF.

Download Free Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 9
Issue Number: 1
First Page: 41
Last Page: 51
Page Count: 11
DOI: 10.2174/1574891X09666140717102358
Global Biotechnology Congress 2017Drug Discovery and Therapy World Congress 2017

Related Journals

Related eBooks

Webmaster Contact: urooj@benthamscience.org Copyright © 2017 Bentham Science